ERBB2 and breast carcinoma: The NSABP B-41 trial (ClinicalTrials.gov ID, NCT01850628; Study registration dates, 2013-05-01), obtained from Georgetown University, is a Randomized Neoadjuvant Trial for HER2-positive operable breast cancer treated with neoadjuvant trastuzumab and chemotherapy (AC + T), with or without lapatinib [19].